The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
Open accessAbstract
BACKGROUND: A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pro, and membrane-linked gp120 (vCP1521), combined with a bivalent gp120 protein boost (AIDSVAX B/E), provided modest protection against HIV-1 infection in a community-based population in Thailand (RV144 trial). No protection was observed in Thai injection drug users who received AIDSVAX B/E alone (Vax003 trial). We compared the neutralizing antibody response in these 2 trials. METHODS: Neutralization was assessed with tier 1 and tier 2 strains of virus in TZM-bl and A3R5 cells. RESULTS: Neutralization of several tier 1 viruses was detected in both RV144 and Vax003. Peak titers were higher in Vax003 and waned rapidly in both trials. The response in RV144 was targeted in part to V3 of gp120.vCP1521 priming plus 2 boosts with gp120 protein was superior to 2 gp120 protein inoculations alone, confirming a priming effect for vCP1521. Sporadic weak neutralization of tier 2 viruses was detected only in Vax003 and A3R5 cells. CONCLUSION: The results suggest either that weak neutralizing antibody responses can be partially protective against HIV-1 in low-risk heterosexual populations or that the modest efficacy seen in RV144 was mediated by other immune responses, either alone or in combination with neutralizing antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Self-citationAntibody neutralization and escape by HIV-1
Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., et al. (2003) · Nature · doi:10.1038/nature01470 · Cited by 2,421
Self-citationBuchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
Self-citationThe HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens
Wyatt, R., & Sodroski, J. (1998) · Science · doi:10.1126/science.280.5371.1884 · Cited by 1,598
Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569 · cited 1×
“TZM-bl is a genetically engineered HeLa cell line (also known as JC53-BL) that expresses CD4, CCR5, and CXCR4 [27] and carries Tat-regulated reporter genes for firefly Luc and Escherichia coli β-galactosidase under regulatory control of an HIV1 long-terminal-repeat sequence [28].”
BackgroundSelf-citationMascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S., Birx, D. L., et al. (2000) · Nature Medicine · doi:10.1038/72318 · Cited by 1,250
Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B., & Kabat, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.4.2855-2864.1998 · Cited by 1,219
Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K. M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10108-10125.2005 · Cited by 1,070
Self-citationRapid cloning of high-affinity human monoclonal antibodies against influenza virus
Wrammert, J., Smith, K., Miller, J., Langley, W. A., Kokko, K., Larsen, C., Zheng, N.-Y., Mays, I., Garman, L., Helms, C., et al. (2008) · Nature · doi:10.1038/nature06890 · Cited by 1,025
Cited by
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Liao, H.-X., Lynch, R., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., Fire, A. Z., Roskin, K. M., Schramm, C. A., Zhang, Z., et al. (2013) · Nature · doi:10.1038/nature12053 · Cited by 988
Self-citationSanders, R. W., Derking, R., Cupo, A., Julien, J.-P., Yasmeen, A., de Val, N., Kim, H. J., Blattner, C., de la Peña, A. T., Korzun, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003618 · Cited by 935
Pardi, N., Hogan, M. J., Naradikian, M. S., Parkhouse, K., Cain, D. W., Jones, L., Moody, M. A., Verkerke, H. P., Myles, A., Willis, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171450 · Cited by 530
Self-citationSarzotti-Kelsoe, M., Bailer, R. T., Turk, E., Lin, C.-L., Bilska, M., Greene, K. M., Gao, H., Todd, C. A., Ozaki, D. A., Seaman, M. S., et al. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.11.022 · Cited by 532
Self-citationHIV‐1 neutralizing antibodies: understanding nature's pathways
Mascola, J. R., & Haynes, B. F. (2013) · Immunological Reviews · doi:10.1111/imr.12075 · Cited by 475
Self-citationBroadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Yates, N. L., Liao, H.-X., Fong, Y., deCamp, A., Vandergrift, N. A., Williams, W. T., Alam, S. M., Ferrari, G., Yang, Z.-Y., Seaton, K. E., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007730 · Cited by 450
Self-citationChung, A. W., Ghebremichael, M., Robinson, H., Brown, E., Choi, I., Lane, S., Dugast, A.-S., Schoen, M. K., Rolland, M., Suscovich, T. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007736 · Cited by 406
Self-citationLiao, H.-X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K.-K., Chen, X., Tsao, C.-Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.11.011 · Cited by 377
Self-citationBonsignori, M., Pollara, J., Moody, M. A., Alpert, M. D., Chen, X., Hwang, K.-K., Gilbert, P. B., Huang, Y., Gurley, T. C., Kozink, D. M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.01023-12 · Cited by 375
Self-citationPrevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
Hraber, P., Seaman, M. S., Bailer, R. T., Mascola, J. R., Montefiori, D. C., & Korber, B. T. (2014) · AIDS · doi:10.1097/qad.0000000000000106 · Cited by 357
Self-citationStrategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Haynes, B. F., Wiehe, K., Borrow, P., Saunders, K. O., Korber, B., Wagh, K., McMichael, A. J., Kelsoe, G., Hahn, B. H., Alt, F., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00753-w · Cited by 352
Self-citationdeCamp, A., Hraber, P., Bailer, R. T., Seaman, M. S., Ochsenbauer, C., Kappes, J., Gottardo, R., Edlefsen, P., Self, S., Tang, H., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02853-13 · Cited by 330
Self-citationCooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies
Gao, F., Bonsignori, M., Liao, H.-X., Kumar, A., Xia, S.-M., Lu, X., Cai, F., Hwang, K.-K., Song, H., Zhou, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.022 · Cited by 279
Self-citationNonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines
Excler, J.-L., Ake, J., Robb, M. L., Kim, J. H., & Plotkin, S. A. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00230-14 · Cited by 114
Self-citation
Metadata
- Authors
- Montefiori, D. C., Karnasuta, C., Huang, Y., Ahmed, H., Gilbert, P., de Souza, M. S., McLinden, R., Tovanabutra, S., Laurence-Chenine, A., Sanders-Buell, E., Moody, M. A., Bonsignori, M., Ochsenbauer, C., Kappes, J., Tang, H., Greene, K., Gao, H., LaBranche, C. C., Andrews, C., Polonis, V. R., Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Self, S. G., Berman, P. W., Francis, D., Sinangil, F., Lee, C., Tartaglia, J., Robb, M. L., Haynes, B. F., Michael, N. L., & Kim, J. H.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-05-25
- Volume
- 206
- Issue
- 3
- Pages
- 431-441
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2108823547
- Cited by
- 284
- References
- 45
- FWCI
- 17.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.